Trovagene, Inc. (NASDAQ:TROV) Files An 8-K Other Events
Item 8.01
Trovagene, Inc. (NASDAQ:TROV) Files An 8-K Other Events
On October 22, 2019, Trovagene, Inc. issued a press release announcing data demonstrating positive response to treatment in patients enrolled in its Phase 1b/2 trial of onvansertib in combination with FOLFIRI and Avastin® (bevacizumab) for second-line treatment of KRAS-mutated metastatic colorectal cancer (mCRC). A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits.
Trovagene, Inc. Exhibit
EX-99.1 2 trovpr102219.htm EXHIBIT 99.1 Exhibit Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer•Highly aggressive KRAS-mutated tumors account for ~50% of metastatic colorectal cancer (mCRC); no targeted treatments available and response to standard-of-care is only 5%•Decreases in tumor KRAS mutational burden in response to treatment with onvansertib in combination with FOLFIRI/Avastin® observed in all patients with a confirmed KRAS mutation •KRAS,…
To view the full exhibit click
EX-99.1 2 trovpr102219.htm EXHIBIT 99.1 Exhibit Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer•Highly aggressive KRAS-mutated tumors account for ~50% of metastatic colorectal cancer (mCRC); no targeted treatments available and response to standard-of-care is only 5%•Decreases in tumor KRAS mutational burden in response to treatment with onvansertib in combination with FOLFIRI/Avastin® observed in all patients with a confirmed KRAS mutation •KRAS,…
To view the full exhibit click
here
About Trovagene, Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.